Literature DB >> 10952950

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.

O Belton1, D Byrne, D Kearney, A Leahy, D J Fitzgerald.   

Abstract

BACKGROUND: The formation of prostacyclin (PGI(2)), thromboxane (TX) A(2), and isoprostanes is markedly enhanced in atherosclerosis. We examined the relative contribution of cyclooxygenase (COX)-1 and -2 to the generation of these eicosanoids in patients with atherosclerosis. METHODS AND
RESULTS: The study population consisted of 42 patients with atherosclerosis who were undergoing surgical revascularization. COX-2 mRNA was detected in areas of atherosclerosis but not in normal blood vessel walls, and there was evidence of COX-1 induction. The use of immunohistochemical studies localized the COX-2 to proliferating vascular smooth muscle cells and macrophages. Twenty-four patients who did not previously receive aspirin were randomized to receive either no treatment or nimesulide at 24 hours before surgery and then for 3 days. Eighteen patients who were receiving aspirin were continued on a protocol of either aspirin alone or a combination of aspirin and nimesulide. Urinary levels of 11-dehydro-TXB(2) and 2,3-dinor-6-keto-PGF(1alpha), metabolites of TXA(2) and PGI(2), respectively, were elevated in patients with atherosclerosis compared with normal subjects (3211+/-533 versus 679+/-63 pg/mg creatinine, P<0.001; 594+/-156 versus 130+/-22 pg/mg creatinine, P<0.05, respectively), as was the level of the isoprostane 8-iso-PGF(2alpha). Nimesulide reduced 2, 3-dinor-6-keto-PGF(1alpha) excretion by 46+/-5% (378.3+/-103 to 167+/-37 pg/mg creatinine, P<0.01) preoperatively and blunted the increase after surgery. Nimesulide had no significant effect on 11-dehydro-TXB(2) before (2678+/-694 to 2110+/-282 pg/mg creatinine) or after surgery. The levels of both products were lower in patients who were taking aspirin, and no further reduction was seen with the addition of nimesulide. None of the treatments influenced urinary 8-iso-PGF(2alpha) excretion.
CONCLUSIONS: Both COX-1 and -2 are expressed and contribute to the increase in PGI(2) in patients with atherosclerosis, whereas TXA(2) is generated by COX-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952950     DOI: 10.1161/01.cir.102.8.840

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  65 in total

Review 1.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

Authors:  Burak Pamukcu; Huseyin Oflaz; Rezzan Deniz Acar; Sabahattin Umman; Nevres Koylan; Berrin Umman; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

3.  Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.

Authors:  Peter B Anning; Barbara Coles; Jonathan Morton; Haibin Wang; Jashim Uddin; Jason D Morrow; Sudhansu K Dey; Lawrence J Marnett; Valerie B O'Donnell
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

4.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

5.  Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys.

Authors:  Min-Jeong Kim; Stal S Shrestha; Michelle Cortes; Prachi Singh; Cheryl Morse; Jeih-San Liow; Robert L Gladding; Chad Brouwer; Katharine Henry; Evan Gallagher; George L Tye; Sami S Zoghbi; Masahiro Fujita; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2018-06-29       Impact factor: 10.057

Review 6.  Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Authors:  Ruth Savage
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 7.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

Review 8.  Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?

Authors:  Laurence G Howes; Henry Krum
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Strong activation of cyclooxygenase I and II catalytic activity by dietary bioflavonoids.

Authors:  Hyoung-Woo Bai; Bao Ting Zhu
Journal:  J Lipid Res       Date:  2008-07-26       Impact factor: 5.922

10.  Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.

Authors:  Masahide Hamaguchi; Takahiro Seno; Aihiro Yamamoto; Masataka Kohno; Masatoshi Kadoya; Hidetaka Ishino; Eishi Ashihara; Shinya Kimura; Yoshinori Tsubakimoto; Hiroki Takata; Toshikazu Yoshikawa; Taira Maekawa; Yutaka Kawahito
Journal:  J Clin Biochem Nutr       Date:  2010-07-03       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.